Jonathon B. Cohen, MD, MS

Articles by Jonathon B. Cohen, MD, MS

The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer Patient

ByCarmelo Blanquicett, MD, PhD, FACP,Theodore Johnson, II, MD, MPH,Christopher Flowers, MD, MS,Jonathon B. Cohen, MD, MS

November 14th 2019

Geriatric assessments have now been recommended as part of the standard evaluation of an older adult considering cancer therapy.

How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis

ByKevin H. Hall, PharmD, BCOP,Elyse Hall Panjic, PharmD, BCOP,Kelly Valla, PharmD, BCOP,Christopher R. Flowers, MD, MS,Jonathon B. Cohen, MD, MS

June 15th 2018

Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.

PI3K Inhibitors: Understanding Toxicity Mechanisms and Management

ByI. Brian Greenwell, MD,Andrew Ip, MD,Jonathon B. Cohen, MD, MS

November 15th 2017

Here, we briefly describe the clinical efficacy of PI3K inhibitors, then discuss the mechanisms and management of the more common unusual toxicities seen with these agents.

A Plethora of Novel Therapies-Which One to Choose?

ByJonathon B. Cohen, MD, MS,Christopher R. Flowers, MD, MS

July 15th 2015

While the headliners for the 2015 ASCO Annual Meeting featured mainly immunologic approaches to cancer treatment, with agents such as nivolumab and ipilimumab, the new data in hematologic malignancies highlighted a large number of novel therapies, each of which appears promising.

Peripheral T-Cell Lymphoma: What’s the Role for Transplant?

ByJonathon B. Cohen, MD, MS,Christopher R. Flowers, MD, MS

September 15th 2013

The number of recently approved agents and those under investigation is promising. However, there are currently no recommendations regarding the optimal timing for use of these agents, a reflection of the lack of data in this area and the need for prospective studies.